Pfizer’s TUKYSA Regimen Obtains FDA Approval As Front-Line Maintenance Treatment For HER2+ Metastatic Breast Cancer
TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, supporting approval as a chemotherapy-free maintenance optionPfizer Inc. (NYSE:PFE) today
Pfizer got permission to sell a new cancer medicine. It helps patients live longer without needing chemotherapy, which is good news for both sick people and the company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.